Onc.AI
Onc.AI is a privately held digital health company on a mission to radically improve oncology decision making. By leveraging a market-leading oncology real-world dataset, Onc.AI develops AI models to fulfill the potential of precision oncology, with products predicting clinical outcomes in metastatic lung cancer to inform pharma clinical development and medical oncologist decision-making.
Industries
Nr. of Employees
small (1-50)
Products
Imaging-based lung clinical management test (investigational)
An imaging AI test that produces patient-specific prognostic risk stratification and standardized imaging biomarker reports to support management of metastatic lung cancer patients.
Serial CT response scoring model (deep-learning) — regulatory-designated
A deep-learning model that scores serial CT studies to assess early therapeutic response; reported to have received FDA Breakthrough Device designation for accelerated regulatory review.
Imaging-based lung clinical management test (investigational)
An imaging AI test that produces patient-specific prognostic risk stratification and standardized imaging biomarker reports to support management of metastatic lung cancer patients.
Serial CT response scoring model (deep-learning) — regulatory-designated
A deep-learning model that scores serial CT studies to assess early therapeutic response; reported to have received FDA Breakthrough Device designation for accelerated regulatory review.
Services
Secure, automated service that ingests routine CT scans, extracts imaging biomarkers, produces patient-specific prognostic scores and delivers clinician-facing reports to inform treatment decisions.
Analytics offering for clinical development teams to support patient stratification, arm balancing, early response assessment and go/no-go decision support using imaging-derived biomarkers.
Secure, automated service that ingests routine CT scans, extracts imaging biomarkers, produces patient-specific prognostic scores and delivers clinician-facing reports to inform treatment decisions.
Analytics offering for clinical development teams to support patient stratification, arm balancing, early response assessment and go/no-go decision support using imaging-derived biomarkers.
Expertise Areas
- Medical imaging AI
- Radiomics and quantitative imaging
- Clinical decision support for oncology
- Clinical trial analytics and patient stratification
Key Technologies
- Deep learning for image analysis
- Radiomic feature extraction
- CT image volumetric analysis
- Cloud-based de-identification pipelines
News & Updates
Onc.AI was awarded FDA Breakthrough Device Designation for Serial CT Response Score Deep Learning Model.
Onc.AI was awarded a $2 million SBIR grant from the National Cancer Institute to advance AI-based clinical decision support for metastatic NSCLC.
An interview with Onc.AI CEO Akshay Nanduri discussing radiomics and deep learning in clinical imaging.
Onc.AI raised $25 million in Series A financing co-led by MassMutual and Action Potential Venture Capital.
Onc.AI raised $6 million in Series Seed financing co-led by Blue Venture Fund and Accomplice.
Onc.AI was awarded FDA Breakthrough Device Designation for Serial CT Response Score Deep Learning Model.
Onc.AI was awarded a $2 million SBIR grant from the National Cancer Institute to advance AI-based clinical decision support for metastatic NSCLC.
An interview with Onc.AI CEO Akshay Nanduri discussing radiomics and deep learning in clinical imaging.
Onc.AI raised $25 million in Series A financing co-led by MassMutual and Action Potential Venture Capital.
Onc.AI raised $6 million in Series Seed financing co-led by Blue Venture Fund and Accomplice.